Twitxy Saved

Olli Lohi

@LohiOlli

Professor of Pediatric Hematology & Oncology at Tampere University
Tampere, Finland Joined July 2014
1.8K Following 976 Followers 2.4K Posts

Latest posts 5

Pinned post

Olli Lohi @LohiOlli
Finally out! Check out this paper @LeukemiaJnl
➡️➡️intensive chemotherapy for high-risk (HR) ALL patients in the NOPHO ALL2008 study 🥳
* Minimized HR allocation ➡️18% of the entire cohort
* Of 314 HR patients (age 1–45), the 5-y EFS 64% (OS 70%)
* B-ALL patients (N=185) had a 5-y EFS of 68% (RR 24%), which was higher than the 59% EFS (RR 23%) for T-ALL (N=129)
* Treatment-related mortality in first complete remission (DCR1) higher for T-ALL at 17%, compared to 8% for BCP-ALL
* Patients stratified by HR genetics (KMT2A, hypo) had EFS of 74%: outcomes limited by treatment toxicity (RR 13%)
* Patients stratified due to inadequate treatment response had an EFS of 58% and RR of 29%
* High WBC counts and adult age (≥18 years) were confirmed as adverse prognostic markers
‼️Results implemented in ongoing ALLTogether trial ➡️➡️ aim to minimize use of the most intensive blocks. 💉📈💡

Thanks to @AtteNikkila and all colleagues 👏👏👏
2 replies 4 reposts 7 likes 1.4K views View on X
Olli Lohi @LohiOlli
In children with newly diagnosed high-risk B-cell ALL, replacement of two cycles of highly toxic conventional chemotherapy with blinatumomab resulted in a significantly greater percentage of patients with event-free survival at 4 years (83% vs 70.3%)👇
NEJM Verified account @NEJM Sep 16
Among children with high-risk B-cell acute lymphoblastic leukemia, two cycles of blinatumomab led to a higher 4-year event-free survival than two cycles of chemotherapy (83.0% vs. 70.3%), with a lower risk of serious infection. Full phase 3 AIEOP-BFM ALL 2017 trial results: nej.md/4dBfwOk

Editorial: Blinatumomab — A New Standard of Care in Acute Lymphoblastic Leukemia nej.md/3UWmKWP
View quoted post on X